Suzhou Alphamab Co., Ltd.
Clinical trials sponsored by Suzhou Alphamab Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New weekly shot aims to stop bleeds in hemophilia patients Results expected Oct 2026 (estimated)
- New IV drug for high blood pressure enters early human testing Results expected Dec 2026 (estimated)
- New obesity drug KN069 enters first human tests Results expected Apr 2027 (estimated)
- New drug aims to stop blood clots during dialysis Results expected Aug 2027 (estimated)
-
New weekly shot aims to stop bleeds in hemophilia patients
Disease control OngoingThis Phase 3 trial tests a new drug called KN057, given as a weekly injection, to prevent bleeding in people with hemophilia A or B who do not have inhibitors. The study includes 125 males aged 12 to 70 with severe or moderately severe hemophilia. Participants are split into grou…
Phase 3 • Sponsor: Suzhou Alphamab Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 18:24 UTC
-
New shot could cut bleeding in Tough-to-Treat hemophilia
Disease control OngoingThis study tests a weekly injection called KN057 to see if it can prevent bleeding episodes in people with hemophilia A or B who have developed inhibitors (antibodies that block standard treatment). About 53 male participants aged 12 to 70 will be randomly assigned to receive KN0…
Phase 3 • Sponsor: Suzhou Alphamab Co., Ltd. • Aim: Disease control
Last updated Jun 26, 2026 18:08 UTC
-
One shot to stop clots? new drug tested in knee surgery patients
Prevention OngoingThis study tests a new drug called KN060, given as a single intravenous dose, to prevent blood clots in people having total knee replacement surgery. It compares KN060 to the standard treatment enoxaparin, which requires daily injections. The trial involves 241 adults and is curr…
Phase 2 • Sponsor: Suzhou Alphamab Co., Ltd. • Aim: Prevention
Last updated Jun 26, 2026 18:15 UTC